Yamaguchi T, Nakanishi M, Yamashita M, Matsumoto H, Nakamura M, Kominami G, Iwatani K, Nakagawa Y, Kono M, Sugeno K
Shionogi Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.
Nihon Yakurigaku Zasshi. 1987 Oct;90(4):239-47. doi: 10.1254/fpj.90.239.
Oral administration of 450191-S to humans at 4 mg/man led to the formation of the same plasma metabolites as those found in animals; i.e., M-1, M-2, M-A, M-3 and M-4. Unlike in animals, M-4 was the major metabolite in human plasma for 6 hr after dosing. 450191-S was not found in human plasma after administration of the commonly used dose of 450191-S (1-2 mg/man). The major human urinary metabolite was also M-4, and 44-68% of the dose was excreted as M-4 into 0-24 hr urine. The unchanged 450191-S excreted into the urine was scarcely detectable. Minor metabolites also seemed to be present in the urine, such as the 4OHM-3 conjugate, M-1 and its conjugate, M-2 and its conjugate, M-A and its conjugate, and M-3 and its conjugate. However, all of them together came to not more than 1% of the dose.